IRONWOOD PHARMACEUTICALS INC
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(a) On November 5, 2026, we issued a press release announcing unaudited financial results for the quarter ended September 30, 2026, which was furnished on a Current Report on Form 8-K filed on November 5, 2026, or the Earnings Press Release. Subsequent to issuing our Earnings Press Release, we identified a clerical error with respect to the amount shown for the cash from operations the Company generated in the quarter ended September 30, 2026. The Earnings Press Release incorrectly reported cash from operations of $130.8 million for the quarter ended September 30, 2026; the correct cash from operations for the quarter ended September 30, 2026 is $67.4 million. We have updated the Earnings Press Release on the Investors & Media section of our website at www.ironwoodpharma.com to reflect the correction made.
(b) During the quarter ended September 30, 2026, no directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.